- Peregrine Pharmaceuticals (PPHM +2.3%) FQ4 results: Revenues: $9.3M (+43.1%); COGS: $4.8M (+26.3%); R&D Expense: $11.5M (+30.7%); SG&A: $5.2M (+18.2%); Operating Loss: ($12.2M) (-16.2%); Net Loss: ($12.1M) (-17.5%); Loss Per Share: ($0.07) (-16.7%).
-
FY2015 results: Revenues: $26.8M (+19.6%); COGS: $15.6M (+19.1%); R&D Expense: $43M (+55.2%); SG&A: $18.7M (+8.1%); Operating Loss: ($50.5M) (-41.5%); Net Loss: ($50.4M) (-42.4%); Loss Per Share: ($0.30) (-36.4%); Quick Assets: $68M (-12.3%).
- No guidance given.